Fundz

MeiraGTx acquires bota-vec from Johnson & Johnson

PUBLIC · MGTXApr 16, 2026

Acquiring Company

MeiraGTx Holdings plc

Acquired Company

Johnson & Johnson's orthopedics unit

PiscatawayBiotechnologyHealth CareGeneticsTherapeuticshospital & health care

Description

On April 16, 2026, MeiraGTx Holdings plc announced its acquisition of botaretigene sparoparvovec (bota-vec) from Johnson & Johnson. This acquisition aims to enhance the development of treatments for X-linked retinitis pigmentosa (XLRP). MeiraGTx plans to pursue global regulatory filings for the therapy to expedite its approval and potential market launch.

Company Information

Company

MeiraGTx Holdings plc

Location

States 450 East 29Th Street

About

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose-responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular diseases, including both inherited retinal diseases as well as large degenerative ocular diseases, neurodegenerative diseases, and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases. For more information, please visit www.meiragtx.com

Fundz sees it the moment MeiraGTx Holdings plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Sarah
Senior decision-maker at this company
••••••••@••••••••

See Sarah's verified email →

Oliver
Likely contact at this company
••••••••@••••••••

See Oliver's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for MeiraGTx Holdings plc's next move

Learn about Strategic plan

Frequently asked

Who acquired Johnson & Johnson's orthopedics unit?

Johnson & Johnson's orthopedics unit was acquired by MeiraGTx Holdings plc. The deal was reported on April 16, 2026. MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx Holdings plc is publicly traded (MGTX) and operates in Biotechnology.

When did MeiraGTx Holdings plc acquire Johnson & Johnson's orthopedics unit?

MeiraGTx Holdings plc's acquisition of Johnson & Johnson's orthopedics unit was reported on April 16, 2026. On April 16, 2026, MeiraGTx Holdings plc announced its acquisition of botaretigene sparoparvovec (bota-vec) from Johnson & Johnson. This acquisition aims to enhance the development of treatments for X-linked retinitis pigmentosa (XLRP). Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Johnson & Johnson's orthopedics unit do?

Johnson & Johnson's orthopedics unit, known as DePuy Synthes, focuses on the production of orthopedic devices. It provides hip, knee, and shoulder implants, along with surgical instruments. The unit generated $9.3 billion in sales in 2025. It is publicly traded (JNJ), operating in hospital & health care, and is based in Piscataway.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.